Specialized Research

VIP

Also known as: Peptídeo Intestinal Vasoativo

Molecular Identifiers

Molecular Formula

C147H237N43O43S

CAS Number

40077-57-4

PubChem CID

53314964

Molecular Weight

3326.82 Da

Overview

28-amino acid neuropeptide with a molecular weight of approximately 3,326.82 Da. Naturally produced in the central and peripheral nervous systems, gastrointestinal tract, and pancreas. Has broad vasodilatory, anti-inflammatory, immunomodulatory, and neuroprotective actions across multiple organ systems.

VIP is an endogenous neuropeptide with broad action via VPAC1 and VPAC2 receptors: potent vasodilation, systemic anti-inflammatory modulation, promotion of immune tolerance, neuroprotection, and regulation of gastrointestinal motility and pancreatic secretion. This multifunctional profile supports research lines in chronic biotoxin-related inflammatory syndromes (CIRS), autoimmune diseases, and gastrointestinal disorders.

Exogenous VIP has no broad regulatory approval. It is prescribed mostly through compounding pharmacies as off-label use, in 4 to 8 week protocols via the subcutaneous or intranasal route (the latter popularized in clinical practices associated with CIRS management). It has a short half-life (1 to 2 minutes in plasma) and limited stability after reconstitution. Due to its vasodilatory effect, blood pressure monitoring is required.

Sequence (1 letter): HSDAVFTDNYTRLRKQMAVKKYLNSILN
Extended notation: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn

Half-life

~1-2 minutes

Administration Route

Intranasal or subcutaneous

Category

Specialized Research

Mechanism of Action

  • Potent vasodilation via VPAC1 and VPAC2 receptors
  • Systemic anti-inflammatory action and cytokine regulation
  • Immune system modulation and promotion of immune tolerance
  • Neuroprotection and nervous system function support
  • Regulation of gastrointestinal motility and pancreatic secretion

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 200 mcg per day inhaled (4 inhalations of 50 mcg)
Frequency 4 times daily
Timing Distributed throughout the day
Duration 12-24 weeks (Petkov et al. 2003 pulmonary hypertension study)

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Hypotension
  • Tachycardia
  • Facial flushing
  • Nausea
  • Diarrhea

Product Properties

Purity >95%
Appearance White lyophilized powder
Solubility Soluble in water and bacteriostatic water
Source Solid-phase peptide synthesis (SPPS)
Storage Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 2 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles.

Presentations & Preparation

Vials of VIP found in the research market:

5 mg10 mg15 mg20 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per 5 mg vial
  • Slowly inject the diluent against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 14 days)
  • Protect from direct light
  • Do not freeze after reconstitution
  • VIP is sensitive to degradation — use soon after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on VIP.

2010 · Am J Respir Crit Care Med

Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis

Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, et al.
2003 · J Clin Invest

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

Bronchogen

1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals

Cardiogen

Chonluten

1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals

Crystagen

1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals